Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21133
Title: Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving estradiol therapy.
Authors: Angus, Lachlan;Leemaqz, Shalem Y;Ooi, Olivia;Cundill, Pauline;Silberstein, Nicholas;Locke, Peter;Zajac, Jeffrey D;Cheung, Ada S
Affiliation: Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Equinox Gender Diverse Health Centre, Thorne Harbour Health, Fitzroy, Australia
Issue Date: 1-Jun-2019
EDate: 2019-06-01
Citation: Endocrine connections 2019; online first: 1 June
Abstract: Estradiol with or without an antiandrogen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy, however there is no evidence to guide optimal treatment choice. We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals. Retrospective cross-sectional study. We analysed 114 transfeminine individuals who had been on estradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; estradiol alone (n=21), estradiol plus cyproterone acetate (n=21) and estradiol plus spironolactone (n=38). Secondary outcomes included serum estradiol concentration, estradiol valerate dose, blood pressure, serum potassium, urea and creatinine. Median age was 27.0 years (22.5, 45.1) and median duration of hormone therapy was 1.5 years (0.9, 2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8nmol/L (0.6, 1.20)) compared with the spironolactone group (2.0nmol/L (0.9, 9.4), p=0.037) and estradiol alone group (10.5nmol/L (4.9, 17.2), p<0.001), which remained significant (p=0.005) after adjustments for estradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily estradiol dose, blood pressure, serum estradiol, potassium or creatinine. The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21133
DOI: 10.1530/EC-19-0272
ORCID: 0000-0003-3933-5708
0000-0001-5257-5525
PubMed URL: 31234145
ISSN: 2049-3614
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.